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Abstract. In the present study, we investigated the effect of 
apigenin, a flavonoid widely present in fruits and vegetables, 
on a tongue oral cancer-derived cell line (SCC-25) and on a 
keratinocyte cell line (HaCaT), with the aim of unveiling its 
antiproliferative mechanisms. The effect of apigenin on cell 
growth was evaluated by MTT assay, while apoptosis was 
investigated by phosphatidyl serine membrane translocation 
and cell cycle distribution by propidium iodide DNA staining 
through flow cytometry. In addition the expression of cyclins 
and cyclin-dependent kinases was evaluated by western blot-
ting. A reduction of apigenin-induced cell growth was found 
in both cell lines, although SCC-25 cells were significantly 
more sensitive than the immortalized keratinocytes, HaCaT. 
Moreover, apigenin induced apoptosis and modulated the cell 
cycle in SCC-25 cells. Apigenin treatment resulted in cell cycle 
arrest at both G0/G1 and G2/M checkpoints, while western blot 
analysis revealed the decreased expression of cyclin D1 and E, 
and inactivation of CDK1 upon apigenin treatment. These 
results demonstrate the anticancer potential of apigenin in an 
oral squamous cell carcinoma cell line, suggesting that it may 
be a very promising chemopreventive agent due to its cancer 
cell cytotoxic activity and its ability to act as a cell cycle 
modulating agent at multiple levels.
Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most wide-
spread cancer with an annual estimated incidence of 263,000 
worldwide, two-thirds of these cases occurring in developing 
countries (1,2). Although its incidence rate is not increasing 
in the general population of Western countries, an increase in 
the number of OSCC cases has been reported in young adults 
in the United States and in some countries of Europe (3-5). 
The 5-year survival rate remains <60% of diagnosed cases, 
depending on the stage of the tumor at presentation, in addi-
tion, OSCC has devastating consequences negatively affecting 
the patients quality of life (5). Therefore, developments of new 
approaches to prevent OSCC occurrence and growth are highly 
desirable.
Epidemiological studies have identified several nutrients 
derived from plants with anticancer properties and, among 
these, flavonoids, a family of polyphenolic compounds, have 
proved to be effective in cancer prevention (6). Apigenin 
(Api) is a flavonoid widely found in fruits such as oranges and 
grapefruits, vegetables and in plant-derived beverages such as 
chamomile, tea and wine (7). Due to its low toxicity and its 
biological activities, i.e. anti-inflammatory and anti-oxidant 
effects, there has been increasing interest in the potential use of 
Api as an anticancer agent (8). Several studies have proved Api 
to be effective in inhibiting tumor growth in vitro in several 
types of cancer cells including breast, cervical, prostate and 
colorectal ones (9-12). The in vivo effectiveness of Api oral 
administration has been demonstrated against prostate cancer 
(13,14). Moreover, the topical application of Api was found to 
counteract skin carcinoma growth in mice (15). Although Api 
has been widely studied the cellular mechanisms responsible 
of its beneficial effects are still far from being completely 
understood and scarce information is available regarding 
the use of Api in oral cancer (16,17). Api anticancer action 
depends on various mechanisms that can vary according to 
cell type and it involves apoptosis, modulation of the cell cycle 
and alteration of kinase pathways (8). Therefore, the aim of 
the present study is to investigate the anti-proliferative effect 
of Api on OSCC cells, elucidating the underlying molecular 
mechanisms. To this end we evaluated Api's effects on tongue 
derived OSCC cell lines, SCC-25 and on the spontaneously 
immortalized keratinocytes, HaCaT.
Materials and methods
Cell lines and materials. SCC-25, derived from a human oral 
squamous cell carcinoma of the tongue (obtained from ATCC, 
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USA) were maintained in DMEM/F12 (Euroclone, Pero, Italy) 
supplemented with 10% fetal bovine serum (FBS) (Euroclone), 
400 ng/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO, 
USA) and 1% penicillin/streptomycin (Euroclone). HaCaT 
cells (obtained from German Cancer Research Center, 
Heidelberg, Germany) were cultured in high glucose DMEM 
(Euroclone) supplemented with 10% FBS and 1% penicillin/
streptomycin. Cells were maintained at 37˚C in a humidi-
fied incubator with 5% CO2. Apigenin (Sigma-Aldrich) was 
dissolved in pure DMSO and subsequently diluted in culture 
medium. DMSO concentration did not exceed 0.1% during 
treatments.
MTT assay. The effect of Api on cell vitality was evaluated 
by thiazolyl blue tetrazolium bromide (MTT) assay. Cells 
were transferred to 96-well plates (5,000 cells/cm2) and were 
incubated with Api for 24 and 48 hours (h). Subsequently, 
the medium was removed and the cells were incubated with 
MTT (Sigma-Aldrich). Four hours later, formazan crystals 
were dissolved with DMSO and the absorbance was recorded 
at 560 nm in a microplate reader (Bio-Rad, Hercules, CA, 
USA). The effect of Api on cell survival was calculated by 
normalizing the data to the absorbance of vehicle-treated cells 
(considered as 100%). The IC50 value was estimated.
Annexin V-propidium iodide assay. In order to evaluate 
Api-induced apoptosis, the FITC conjugated Annexin 
V-propidium iodide (PI) apoptosis detection kit (BD 
Biosciences, Buccinasco, Italy) was used according to the 
manufacturer's instructions. Briefly, the cells were plated in 
6-well plates (5,000 cells/cm2) and treated for 24 h with Api 
100 µM. Both floating and attached cells were harvested, 
washed with PBS and, finally, suspended in binding buffer 
containing Annexin V and PI. After 15-min incubation in 
the dark, the presence of apoptotic cells was analysed by the 
FACSCantoI flow cytometer (BD Biosciences).
Analysis of cell cycle distribution. After Api treatment, both 
floating and attached cells were harvested, washed twice with 
cold PBS, spun in a refrigerated centrifuge at 200 g for 10 min 
and resuspended in cold 70% ethanol overnight (ON) at 4˚C. 
The following day the cells were washed in cold PBS and then 
incubated in 5 µg/ml PI and 12.5 µg/ml RNAse (both from 
Sigma-Aldrich) for 48 h. When the cell synchronization was 
required, SCC-25 and HaCaT cells were maintained in serum-
free medium for 30 and 48 h, respectively, and subsequently 
treated with Api in complete medium. DNA content analysis 
was subsequently performed by means of a FACSCantoI flow 
cytometer (BD Biosciences, Buccinasco, Italy) and ≥20,000 
events were analyzed. Cell cycle distribution was then 
analyzed by ModFit LT (Verity House Software, Topsham, 
ME, USA).
Western blotting. The Api-treated and control cells were 
washed twice in cold PBS and lysed in 50 mM HEPES, pH 7.5, 
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM 
MgCl2, 5 mM EGTA, 4 mM phenylmethylsulfonyl fluoride, 
1% aprotinin, 10 mM sodium orthovanadate, 20 mM sodium 
pyrophosphate (all from Sigma-Aldrich). The lysates were 
clarified by centrifugation at 13,000 g for 15 min at 4˚C and the 
total protein content was evaluated with a Coomassie Protein 
Assay Reagent kit (Pierce, Rockford, IL, USA). Cell lysates 
(50 µg), mixed with Laemmli buffer (5% β-mercaptoethanol, 
10% SDS, 50% glycerol, 400 mM Tris-HCl (pH 6.8) and 
0.5% bromophenol blue) (all from Sigma-Aldrich), were 
resolved overnight in a 13% SDS-PAGE and then electrob-
lotted onto nitrocellulose membranes (GE Healthcare Life 
Science, Milan, Italy).
Non-specific binding sites were blocked by 1 h room 
temperature (RT) incubation in 5% non-fat milk in TBS 
(10 mM Tris-HCl pH 8, 150 mM NaCl, 0.05% Tween-20). 
Subsequently, membranes were incubated overnight with the 
following primary antibodies diluted in TBS plus 5% non-fat 
milk: cyclin D1, cyclin E (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), Actin (Santa Cruz Biotechnology), cyclin-
dependent kinase 1 (CDK1), phospho-CDK1 (Cell Signaling 
Technology, Danvers, CA, USA). Unbound antibodies were 
removed by TBS washing and the membranes were subse-
quently incubated with peroxidase-conjugated specific 
secondary antibodies for 1 h at RT. Finally, the immune 
complexes were visualized using an enhanced chemilumi-
nescence (ECL) system (Genespin Srl., Milan, Italy). After 
blot scanning, the densitometric analysis of the bands was 
performed using the Gel Logic 100 Imaging System (Eastman 
Kodak, Rochester, NY, USA). Results were expressed as a 
relative optical density (OD) considering the ratio between the 
optical density of the protein band of interest and that of the 
corresponding actin band.
Statistical analysis. Data are reported as means ± standard 
deviation from at least three independent experiments. The 
statistical evaluation of the results was performed using 
GraphPad Prism 3 Software (GraphPad Softwar Inc., La Jolla, 
CA, USA). The differences between controls and treated cell 
MTT results were analyzed by the one-way ANOVA analysis 
of variance followed by Dunnett's multiple comparison 
test. Differences in the percentages of apoptotic cells in the 
Annexin V-PI assay and differences in the cell cycle distri-
bution between controls and treated cells were analyzed by 
Student's t-test. Statistical significance was set at p<0.05.
Results
Apigenin treatment inhibits cell proliferation. The effect of 
different Api concentrations on cell survival was evaluated 
using MTT assay. The data obtained showed a dose- and time-
dependent decrease in cell vitality in both HaCaT and SCC-25 
cells (Fig. 1).
As can be observed in the graph of Fig. 1A, the highest 
doses of Api used induced a marked, statistically significant, 
decrease in SCC-25 cells survival after 24-h treatment, in 
particular Api 50 and 100 µM reduced cell viability to values 
<50% with respect to untreated controls. The Api-induced 
decrease in cell viability was observed also in HaCaT cells; 
however, the effect of Api in these cells was milder than in 
SCC-25 cells, in fact, only Api 100 µM significantly affected 
HaCaT cell viability.
After 48-h treatment all the tested doses statistically 
significantly reduced SCC-25 cells viability, in particular 
a dramatic drop in cell vitality to 18.1±7.% and 7.9±2.0% 
INTERNATIONAL JOURNAL OF ONCOLOGY  43:  1675-1682,  2013 1677
was observed after 48-h treatment with 50 and 100 µM Api, 
respectively. The Api-induced decrease in cell viability with 
respect to vehicle-treated cells was observed also in HaCaT 
cells; however, the effect of Api in these cells was milder than 
in SCC-25 cells, in fact, only Api 100 µM reduced HaCat cell 
viability below 50% (Fig. 1B).
Apigenin induces apoptosis in SCC-25 cells. To assess if the 
Api-induced decrease in cell survival was related to apoptosis, 
we performed a flow cytometric analysis of the membrane 
translocation of phosphatidyl serine with FITC-conjugated 
Annexin V (A), combined with PI DNA staining (PI). As 
shown in Fig. 2A, 24 h exposure to 100 µM Api significantly 
increased the percentage of apoptotic SCC-25 cells (A+/PI-). 
In particular, the population of cells showing A+/PI- increased 
from <1.47±0.78% in the controls to 19.8±4.1% in Api-treated 
cells (p<0.01), whereas the percentage of cells in late apop-
tosis, being positive for both Annexin V and PI staining (A+/
PI+), increased from 4.73±0.74 in the controls to 14.6±2.05% in 
Api-treated cells (p<0.01) (Fig. 2A). On the contrary, 100 µM 
Api treatment induced only a slight, statistically insignificant, 
increase in the percentage of early and late apoptotic cell 
populations in HaCaT cells (Fig. 2B).
Cell cycle alteration induced by apigenin. We aimed at 
correlating the Api-induced inhibition of cell growth with 
an alteration of the cell cycle progression. Therefore, we 
performed cell cycle analysis in cells treated with the most 
effective dose of Api (100 µM) for 24 and 48 h.
An increase in the percentage of cells in the G2/M phase 
in Api-treated cells was observed in both HaCaT and SCC-25 
cells compared with untreated controls. This increase was 
associated with a slight, but statistically significant, decrease 
in the percentage of cells in both G0/G1 and S phase after 48 h 
exposure. The modulation of SCC-25 cell cycle distribution 
due to Api, although already notable after 24 h Api exposure, 
became statistically significant after 48 h (Fig. 3A), so that 
Api 100 µM treatment resulted in 48.2±4% of cells in G2/M, 
versus the 9.3±0.8% observed in controls (Fig. 3A). In HaCaT 
cells, 48 h Api treatment resulted in an increase in the G2/M 
population from 7.1±1.7 in controls to 26.1±1 % in treated cells 
(p<0.001) (Fig. 3B).
Despite the increase in the G2/M population, there was 
a considerable number of cells still in the G0/G1 phase, thus 
suggesting that another checkpoint might be involved in 
Api-induced modulation of cell cycle progression. In an 
attempt to better clarify the effect of Api on cell cycle distribu-
tion, we analyzed the effect of 100 µM Api on synchronized 
cells. For this purpose, SCC-25 and HaCaT cells were main-
tained in serum-free medium for 30 and 48 h, respectively, 
then cells were allowed to re-enter the cell cycle by culturing 
them in complete medium. As shown in Fig. 4, we obtained 
Figure 1. Effect of apigenin on cell survival. Cells were treated with DMSO 
0.1% or Api (25, 50 and 100 µM) and incubated for 24 and 48 h. (A) SCC-25 
cells. (B) HaCaT cells. Cell survival was evaluated by MTT assay. Data rep-
resent percentages of cell viability in comparison to untreated control cells 
that were arbitrarily set to 100% and are reported as the means ± SD of three 
independent experiments. #p<0.05; *p<0.01 versus vehicle-treated group, 
one-way ANOVA, Dunnett's post-test.
Figure 2. Analysis of apoptosis by Annexin V (A)/propidium iodide (PI) 
staining. SCC-25 (A) and HaCaT cells (B) were incubated with 100 µM Api 
for 24 h and then stained with FITC conjugated Annexin V and propidium 
iodide. Live cells are A-P-, early apoptotic cells are A+PI-, cells late in apop-
tosis or necrotic cells are A+PI+, while necrotic cells are A-PI+. Data represent 
percentages of cells, reported as means ± SD of three independent experi-
ments. #p<0.05; *p<0.01 versus CTRL, Student's t-test.
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satisfactory synchronization, with almost 90% of cells being 
in the G0/G1 phase following serum starvation. Api treatment 
on synchronized HaCaT and SCC-25 cells resulted in the 
maintainance of cells into the G0/G1 phase, in fact, while in 
untreated controls the majority of cells after 24 h were in the 
S phase as a result of cycle re-entering after serum starvation, 
Api-treated cells maintained the same distribution of serum 
starvation synchronized cells both after 24 and 48 h of treat-
ment (Fig. 4). In synchronized SCC-25 cells, the exposure to 
100 µM Api for 24 h resulted in 85.7±11.5% of cells being 
in G0/G1 (p<0.01 versus controls) and a very similar effect 
was observed in HaCaT cells. The blockage of cells in G0/G1 
persisted also after 48 h treatment. Despite this, the blockage 
at G2/M transition was still evident in HaCaT cells since a 
slight, but statistically significant (p<0.01), increase in the 
percentage of cells in G2/M was found in 24 h Api-treated cells 
when compared to controls.
Apigenin inactivates CDK1 in SCC-25 cells. In order to 
address in more detail the effect of Api on the cell cycle, we 
evaluated the expression of some cyclins and the associated 
CDKs that regulate both G0/G1 and G2/M phase transition.
Therefore, we considered the protein level of cyclin B1, 
which is involved in G2/M transition, in unsynchronized cells. 
However, no significant modulations of its expression by Api 
were evidenced either in SCC-25 or in HaCaT cell lines (data 
not shown). We subsequently evaluated the level of the CDK1, 
also known as p34cdc2, which is functionally associated with 
cyclin B1. Even in this case we did not observe any variation/
modulation between treated and control cells. Nevertheless 
Figure 3. Effect of Api on cell cycle distribution in unsynchronized cells. 
SCC-25 cells (A) and HaCaT cells (B) were treated with 100 µM Api for 24 
and 48 h. Data represent percentages of cells in G0/G1, S and G2/M phases and 
are reported as the means ± SD of three independent experiments. #p<0.05 
versus CTRL 48 h; *p<0.01 versus CTRL 48 h; §p<0.001 versus CTRL 48H, 
Student's t-test.
Figure 4. Effect of Api on the cell cycle distribution in synchronized cells. SCC-25 cells (A) and HaCaT cells (B) were synchronized by serum starvation for 
30 and 48 h, respectively. Subsequently cells were treated with 100 µM Api in complete medium for 24 and 48 h. Data represent percentage of cells in G0/G1, 
S and G2/M phases and are reported as the means ± SD of three independent experiments. 
#p<0.05 versus CTRL 48 h; *p<0.01 versus CTRL 24 h; @p<0.01 
versus CTRL 48 h, §p<0.001 versus CTRL 24 h, Student's t-test.
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the regulation of CDK1 is quite complex; in fact, it is strictly 
regulated by phosphorylation so that its enzimatic activity is 
inhibited by phosphorylation on the tyrosine in position 15. 
Therefore, we evaluated the level of the tyrosine 15 phosphory-
lated form of CDK1. As shown in Fig. 5, a marked, although not 
statistically significant, increase in tyrosine 15 phosphorylated 
CDK1 was observed in SCC-25 cells following 100 µM Api 
treatment for 24 h (Fig. 5C), whereas Api treatment did not 
modulate the level of tyrosine 15 phosphorylation in HaCaT 
cells (Fig. 5D).
Apigenin modulates cyclin D1 and E expression. In view of the 
different Api action on the cell cycle in synchronized versus 
asynchronous cells, we analyzed also the cyclins and CDKs 
involved in the regulation of G0/G1 transition in synchronized 
cells. First, we evaluated the expression of cyclin D1, which 
drives the progression through the G1 phase of cell cycle, by 
exposing synchronized cells to 100 µM Api for 24 h. As can be 
seen in Fig. 6, Api treatment modulated cyclin D1 expression 
in both cell lines, with a statistically significant decrease being 
observed in SCC-25 cells (Fig. 6C), while the decrease in 
cyclin D1 was slight in HaCaT cells (Fig. 6B and D). Secondly, 
we evaluated the Api effect on the expression of cyclin E, 
whose levels are generally high during the mid G1 phase and 
which is involved in the regulation of G1/S transition. We did 
not find any cyclin E expression in SCC-25 cells (data not 
shown). On the contrary, a statistically significant decrease 
in HaCaT cells after Api treatment was found. The level of 
cyclin E expression significantly dropped after 24 h Api treat-
ment in HaCaT cells (Fig. 7).
Discussion
Apigenin, a flavonoid belonging to the class of flavones has 
proved its effectiveness against various cancer types (8-13), but 
up to now scarce data are available regarding the Api effects 
and molecular mechanisms on OSCC.
In the present study, we aimed at evaluating Api's action on 
OSCC using the cell line SCC-25, derived from tongue OSCC. 
In addition, Api's effect was analyzed also on a spontane-
ously immortalized, non-tumorigenic, keratinocyte cell line: 
HaCaT cells. These cell lines have been widely used and they 
represent a valid model for studying the action of potential 
chemotherapeutic agents (18,19). In addition, HaCaT cells 
may be considered a good model of the initial transformation 
of squamous cell carcinoma. In fact, although they can be 
referred to as normal keratinocytes, they show some molecular 
alterations, found in the first steps of malignant transformation 
of epithelial cells, such as the mutations in both p53 alleles 
(20).
We demonstrated that Api inhibits cancer cell growth 
in vitro; it was able to significantly decrease cell survival 
in SCC-25 cells. In our paradigm, the SCC-25 cells were 
much more sensitive to Api than immortalized keratinocytes 
(HaCaT). In agreement with our findings a selective growth 
inhibitory effect of Api in prostate cancer cells when  compared 
with non-transformed cells was reported (9). Masuelli and 
colleagues (17) also reported a comparable proliferation inhi-
bition in SCC-15, OSCC derived cells.
Consistent with data reported in breast (10) and in lung 
cancer (21), the analysis of the phosphatidyl serine membrane 
Figure 5. Effect of Api on tyrosine 15 phosphorylated CDK1 (pCDK1) expression. Cells were cultivated for 24 h in the presence of 100 µM Api (A100), control 
is represented by untreated cells (CTRL). Representative western blot showing protein level of pCDK1 in SCC-25 cells (A) and in HaCaT cells (B). Anti-actin 
immunoblotting was performed as internal loading control. Graphs show the relative levels of optical density of pCDK1 bands normalized to the expression 
of actin in SCC-25 cells (C) and in HaCaT cells (D). Data are reported as means ± SD of three independent experiments.
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translocation, an early apoptotic marker, showed that Api 
induced apoptosis in SCC-25 cells. Apoptosis was not detected 
in HaCaT cells, thus confirming a selective cytotoxic action of 
Api towards tumoral SCC-25 cells. The absence of apoptosis 
in HaCaT cells is not in agreement with previously reported 
data from Abu-Yousif et al (22), where the exposure of HaCaT 
cells to Api led to apoptosis in almost 15% of cells. One 
possible reason for this difference might be that in the study 
of Abu-Yousif et al Api treatment was conducted in serum-
free medium, while in the present study HaCaT cells were 
maintained in complete medium during evaluation of Api 
cytotoxicity. However, the ratio of apoptotic cells alone was 
not enough to explain the decrease in cell viability observed 
in SCC-25 cells following Api treatment. Furthermore, the 
absence of apoptosis in HaCaT cells, whose proliferation was 
inhibited by Api, led us to hypothesize that mechanisms other 
Figure 6. Api effect on cyclin D1 expression in synchronized cells. Cells were cultivated for 24 h in the presence of 100 µM Api (A100), control is represented by 
untreated cells (CTRL). Representative western blot showing protein level of cyclin D1 in SCC-25 cells (A) and in HaCaT cells (B). Anti-actin immunoblotting 
was performed as internal loading control. Graphs show the average levels of cyclin D1 in SCC-25 cells (C) and in HaCaT cells (D), expressed as relative level 
of optical density of cyclin D1 bands normalized to the expression of actin and they are reported as the means ± SD of three independent experiments. 
#p<0.05 
versus CTRL, Student's t-test.
Figure 7. Api effect on cyclin E expression in HaCaT cells. (A) Representative western blot showing protein levels of cyclin E. Cells were synchronized by 
serum starvation for 48 h and subsequently treated with 100 µM Api (A100) in complete medium for 24 h. Controls (CTRL) are synchronized cells that did 
not receive Api. Anti-actin immunoblotting was performed as internal loading control. (B) Graphs show the relative levels of optical density of cyclin E bands 
normalized to the expression of actin. Data are reported as the means ± SD of three independent experiments. *p<0.01 versus CTRL, one-way ANOVA test, 
Tukey's post-test.
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than apoptosis had a role in the cell number decrease observed 
after Api treatment. We therefore investigated whether the 
impairment of cell growth was associated with alterations in 
the cell cycle progression. The analysis of cell cycle distribu-
tion showed a marked increase in the percentage of cells in the 
G2/M phase after Api treatment in both cell lines. These results 
are in agreement with data reported by Ujiki et al (23) and Choi 
and Kim (10) that demonstrated an Api-induced G2/M arrest 
in pancreatic and breast cancer cells, respectively. In addition, 
an increase in the G2/M population after Api exposure was 
observed also in immortalized keratinocytes (24,25) and in 
primary cultures of OSCC (16). On the contrary, our results 
differ from the data reported by Masuelli and co-workers 
(17). Although they reported an Api-induced decrease in 
cell survival similar to our findings, they found a significant 
decrease in cells in both G1 and G2/M phases after Api expo-
sure in SCC-15. The main regulator of G2/M progression is the 
CDK1/cyclin B complex whose activity is required for cells 
to enter mitosis. In our paradigm, Api induced only a slight 
modulation of the level of cyclin B and CDK1 (data not shown). 
However, CDK1 activity is also regulated by phosphorylation 
and dephosphorylation mediated by wee1 and cdc25 and, in 
particular dephosphorylation of CDK1 at the tyrosine 15 site 
is required for its activity (26). Api treatment induced a signifi-
cant increase in the level of tyrosine 15 phosphorylated CDK1 
in SCC-25 cells, thus indicating that Api can inactivate this 
CDK. Similar results were obtained in human melanoma cells 
(27). Api's ability to inactivate CDK1 through phosphorylation 
on tyrosine 15 sites was demonstrated also by McVean et al 
(25) in epidermal keratinocytes. On the contrary, HaCaT cells 
did not show any modulation of CDK1 phosphorylation after 
Api treatment, thus indicating that Api induces G2/M arrest 
through of different mechanisms in different cell types.
Even after 48 h Api exposure, a relatively large percentage 
of cells still remained in the G0/G1 phase leading us to 
hypothesize that Api could also impair G1 progression. Api 
treatment in synchronized cells resulted in an almost complete 
G0/G1 arrest in both the cell lines. These data are consistent 
with results by Lepley and Pelling (28) who reported a G1 
accumulation in synchronized skin fibroblasts exposed to 
Api, while unsynchronized cells were arrested in G2/M. 
Western blot analysis demonstrated that Api-induced G0/G1 
arrest depended on different pathways in SCC-25 and HaCaT 
cells. A statistically significant decrease in the expression of 
the cyclin E cell was found in HaCaT, whereas we found no 
expression of this cyclin in SCC-25 cells, although cyclin E 
overexpression is often found in oral cancer (29). However, 
the loss of cyclin E expression has been reported in two other 
tongue-derived SCC cell lines (30). It is, therefore, conceivable 
that cell growth deregulation in SCC-25 cells might depend on 
the loss of cyclin E. These observations suggest that Api has 
a double action on the cell cycle, inducing both a G0/G1 and 
a G2/M arrest, accompanied by a reduction in cyclin D1 and 
cyclin E expression and inactivation of CDK1.
In conclusion, we demonstrated an inhibitory effect on 
cell survival and apoptotic effect of Api in oral cancer cells. 
The model of action we hypothesize implies the induction of 
apoptosis in SCC-25 cells by Api, which also determines the 
cell cycle arrest acting as a CDK1 inhibitor and inducing a 
decrease in cyclin D1 expression.
Therefore, it appears that Api deserves to be further studied 
as a potential agent for oral cancer prevention and treatment 
since it is able to induce cell cycle arrest and apoptosis in 
OSCC cells. In addition, Api seems to be a very promising 
cell cycle regulating agent since it is able to induce a double 
cell cycle arrest in different phases. It could, therefore, be 
capable of arresting cell cycle progression also in cells, such as 
SCC-25 where the cycle regulation machinery is deregulated 
but not completely compromised.
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